Eric K. Rowinsky, M.D.

Chairman of the Board, Navidea Biopharmaceuticals
Executive Chairman and President, Rgenix, Inc.

Eric K. Rowinsky, M.D. was appointed Navidea’s Chairman of the Board in September 2016, and has served as a director of Navidea since July 2010. He is Executive Chairman and President of Rgenix, Inc., having served since June 2015. He has also been the Head of Research and Development, Executive Vice President, and Chief Medical Officer of Stemline Therapeutics, Inc., from 2012 to 2015, and was the Chief Executive Officer and Founder of Primrose Therapeutics from August 2010 to September 2011, at which time it was acquired by Stemline. From 2005 to December 2009, he served as the Chief Medical Officer and Executive Vice President of Clinical Development and Regulatory Affairs of ImClone Systems Incorporated, a life sciences company which was acquired by Eli Lilly. Prior to that, Dr. Rowinsky held several positions at the Cancer Therapy & Research Center’s Institute of Drug Development, including Director of the Institute, Director of Clinical Research and SBC Endowed Chair for Early Drug Development, and concurrently served as Clinical Professor of Medicine in the Division of Medical Oncology at the University of Texas Health Science Center at San Antonio. Dr. Rowinsky was an Associate Professor of Oncology at the Johns Hopkins University School of Medicine, and on active staff at the Johns Hopkins School of Medicine from 1987 to 1996. Dr. Rowinsky is a member of the boards of directors of Biogen Inc., BIND Therapeutics, Inc., and Fortress Biosciences, Inc., publicly-held life sciences companies. He is also an Adjunct Professor of Medicine at New York University. Dr. Rowinsky has extensive research and drug development experience, oncology expertise, corporate strategy and broad scientific and medical knowledge.

Michael M. Goldberg, M.D.

President and Chief Executive Officer

  • Member of Navidea’s Board of Directors since November 2013
  • Managing Partner of Montaur Capital Partners since January 2007
  • Previously CEO of Emisphere Technologies
  • Previously Vice President of The First Boston Corp., founding member of the healthcare banking group
  • BS/MD – Combined 6 year biomedical program, RPI/Albany Med
  • MBA finance, Bronfman Fellow – Columbia Grad School of Business

Mark I. Greene, M.D., Ph. D., FRCP

Director of the Division of Immunology, University of Pennsylvania School of Medicine

Mark I. Greene, M.D., Ph. D., FRCP, has been a Navidea Board Director since his appointment in March 2016. Mark has been Director of the Division of Immunology, Department of Pathology at the University of Pennsylvania School of Medicine since 1986. Dr. Greene was the Associate Director of the Division for Fundamental Research, University of Pennsylvania Cancer Center from 1987-2009 and has been the John Eckman Professor of Medical Science of the University of Pennsylvania School of Medicine since 1989. From 1980 to 1986, he served as an Associate Professor at both Harvard University and Harvard Medical School. His groundbreaking work in erbB receptor ... function led to the development of Herceptin (Genentech), and to the development of a proprietary method for the rapid, reliable design of allosteric inhibitors of receptors and enzymes. Dr. Greene currently serves as a Member of the Scientific Advisory Board of Navidea’s subsidiary Macrophage Therapeutics. He previously served as a scientific advisor to Ception Therapeutics, Antisome PLC and Fulcrum Technologies and also served as a Member of the Scientific Advisory Boards of Fulcrum Pharmaceuticals, Inc. and Tolerx, Inc. He previously served as an Emeritus Director of Emisphere Technologies, Inc. where he also served as a Director. Additionally, Dr. Greene served as a Director of Ribi Immunochem Research, Inc., and currently serves as a Consultant of Martell Biosystems, Inc. Dr. Greene has an outstanding record of contributions to cancer biology and drug discovery that is well-documented in over 400 publications. Dr. Greene is a recipient of many awards and patents and has collaborated with a number of pharmaceutical companies. He received his M.D. (1972) and Ph.D. (1977) from the University of Manitoba, Canada, became a Fellow of the Royal College in 1976 and then joined the faculty of Harvard Medical School in 1978.

Michael Rice

Founding Partner, LifeSci Advisors, LLC and LifeSci Capital, LLC

Michael Rice has been a member of the Navidea Board of Directors since 2016. Mr. Rice is a founding partner of LifeSci Advisors, LLC and LifeSci Capital, LLC, companies which he co-founded in March 2010. Prior to co-founding LifeSci Advisors and LifeSci Capital, Mr. Rice was the co-head of health care investment banking at Canaccord Adams, where he was involved in debt and equity financing. Mr. Rice was also a Managing Director at ThinkEquity Partners, where he was responsible for managing Healthcare Capital Markets, including the structuring and execution of numerous transactions. Prior to that, Mr. Rice served as a Managing Director at Bank of America serving large hedge funds and private equity healthcare funds. Previously, he was a Managing Director at JPMorgan/Hambrecht & Quist. Mr. Rice currently serves on the board of directors of RDD Pharma, a specialty pharmaceuticals company. Mr. Rice received a B.A. from the University of Maryland.